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Should smokers be advised to cut down as well as
quit?
Paul Aveyard and Nicola Lindson-Hawley say that reducing smoking is a worthwhile step towards
cessation, but Gerard Hastings and Marisa de Andrade argue that the lifelong nicotine replacement
therapy being recommended in support may benefit industry more than public health
Paul Aveyard professor of behavioural medicine 1, Nicola Lindson-Hawley research fellow 1, Gerard
Hastings professor 2 3 4, Marisa de Andrade impact fellow 2
1Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford OX2 6GG; 2Stirling University, Stirling, UK; 3Open University,
UK; 4L’École des Hautes Etudes en Santé Publique, France
Yes—Paul Aveyard and Nicola
Lindson-Hawley
Currently, more than half of all smokers in England are trying
to reduce the number of cigarettes that they smoke.1 It seems
perverse to discourage this positive behavioural change, but is
it useful to encourage more smokers to cut down and to support
those who do? We believe that it is.
Cutting down aids quitting
People who are cutting down are more likely to attempt to quit
and to succeed than are those who are not cutting down.2 This
may be down to motivation to stop. People who are not cutting
down are probably less motivated to stop than people who are.
However, even when we take every possible step to adjust for
differences in motivation, people who are cutting down are more
likely to make a future quit attempt than people who are not.3
There are some good reasons why reduction might promote
cessation. Nicotine addiction leads to neuroadaptation, and
cutting down on smoking might reverse some of this, leading
to less craving and withdrawal after stopping—the primary
drivers of relapse.4 Reduction may weaken the conditioned
response created by smoking, making relapse less likely to be
triggered by exposure to cues to smoke after quitting. In
addition, reduction is more similar than abstinence to the
smoker’s current behaviour, and this could increase smokers’
confidence that they might succeed.
However, despite showing that reducers are more likely to quit
than non-reducers, the evidence shows that people are not very
successful at cutting down, with reducers smoking only about
two cigarettes a day fewer than non-reducers.5 Teaching people
methods to help them cut down seems to increase reduction and
the chance of achieving cessation.6 There is little evidence that
smokers are using behavioural methods of reduction, and the
development of programmes and self help methods to assist
reduction might lead to better outcomes than are currently
achieved.
As well as behavioural methods, we might achieve a greater
rate of cessation by encouraging reducers to use nicotine
replacement. Randomised trials provide evidence that nicotine
replacement therapy (NRT) can double the rate at which reducers
eventually stop smoking.7Many people and some doctors worry
that nicotine itself is toxic, but any harmwill be trivial compared
with the harm that arises from smoking tobacco.8 As has been
said, people smoke for the nicotine but die from the tar.9 Only
aminority of people who are reducing use nicotine replacement.1
Greater promotion of smoking reduction and using nicotine for
this would mean that more people stop smoking.
Stopping and reducing are not dichotomous
The argument against encouraging and supporting reduction is
that it may divert smokers from stopping to reducing. This
argument rests on the evidence that cutting down without
stopping smoking does not reduce risk or improve health.10 The
fear of promoting cutting down as well as cessation is based on
the belief that smokers may take the easy route of cutting down
alone and not stop altogether. There is no evidence for this
belief. People who are cutting down report that they are doing
so mainly with a view to stopping completely.11 When people
who are trying to stop smoking are observed each day they cycle
rapidly between trying to stop and trying to cut down,12
suggesting that cutting down and stopping are not the dichotomy
that this debate presupposes. Even in people following formal
programmes, those who follow a reduction programme before
quitting and those who follow the traditional abrupt route have
similar rates of quitting.13 We will never know what promoting
reduction will achieve or risk unless we do it. However, formal
modelling as well as the behaviour of smokers who cut down
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give us confidence that risks are low and the potential gains are
great.14
Electronic cigarettes can support reduction, and the great
increase in their popularity shows that people who smoke are
keen to reduce and stop.1 We know already that e-cigarettes
function like any other form of nicotine replacement therapy
but seem to be more attractive to smokers.15 They are now the
most commonly used cessation aid in England.1 About one in
six English smokers uses electronic cigarettes concurrently with
smoking, and these people are doing so without any official
encouragement or support from health education or health
professionals.1 We seem to be approaching the situation where
we have a genuinely desirable alternative to the cigarette. Using
the best behavioural science, we can capitalise on this consumer
movement and accelerate the end of cigarette smoking.
No—Gerard Hastings and Marisa de
Andrade
The UK National Institute for Health and Care Excellence
(NICE) now recommends that people who cannot quit smoking
should be supported to cut down with long term use of nicotine
replacement therapy.16 Over the past decade and a half, tobacco
control in the UK has become increasingly focused on the battle
that would-be quitters fight against their addiction to nicotine.
From this perspective, the key public health challenge is to help
break this dependency or, failing that, at least to make the
dependency less harmful. Nicotine replacement therapy such
as patches, gum and inhalers, other drug treatments including
antidepressant bupropion and nicotine suppressor varenicline,
intensive cessation services, cutting down smoking before
quitting, and now cutting down whether you intend to quit or
not, are all strategies that have resulted from this thinking.
The desire to rehabilitate nicotine and to present tar as the only
villain has also followed. “People smoke for the nicotine but
die from the tar” has become a remarkably popular quote in UK
tobacco control circles.9 However, it comes from a paper that
rejected both prevalence reduction and cutting down strategies
as unrealistic, recommending instead that tobacco control focus
on reducing the tar content of cigarettes. In fact, low tar proved
to be a chimera that the tobacco industry exploited very
effectively.17Now the newly landed, tar-free electronic cigarette
has resuscitated the idea of cleaner cigarettes. When the only
obstacle to progress on preventing the harms of smoking is the
user’s dependence, e-cigarettes offer the beguiling prospect of
addicted smokers migrating painlessly to safer mechanisms of
nicotine delivery.
However, this thinking is by no means universally accepted. In
particular, other jurisdictions are not welcoming the e-cigarette
with the UK’s enthusiasm. Australia, for example, has taken a
more cautious approach. Products that contain nicotine
contravene existing legislation on poisons and so are banned
unless they have been proved to work as cessation aids—and
so far none have been deemed to pass this test.
Internet sales mean that e-cigarettes are being used in Australia,
but in very small numbers, and they have none of the UK’s
evocative marketing, childish flavourings, and colonisation of
point-of-sale space so recently liberated from tobacco.18 19
Mike Daube, professor of health policy at Curtin University,
director of the Public Health Advocacy Institute in Perth, and
president of the Australian Council on Smoking and Health,
said, “All [Australian] governments and major health agencies
are holding very firm on a precautionary position—there is no
compelling evidence that they [e-cigarettes] are any better than
other cessation products; little is known about long-term use;
there is worrying evidence about use by young people elsewhere;
massive concern about tobacco industry
involvement/promotion/normalising smoking . . . and, of course,
in Australia we have made pretty good progress thus far [in
reducing smoking prevalence] and we are looking for a further
decline, especially with government committed to four
successive years of substantial excise duty increases” (personal
communication, 30 April 2014).
The Australian strategy is core public health: cautious, evidence
based, leery of disease vectors, and led by population level
measures. The divergence from the UK strategy stems from a
different characterisation of smoking, which is seen not just as
a matter of individual dependence but as a social, political, and
business phenomenon involving multiple vested interests—less
a dyad between smoker and nicotine andmore a danse macabre.
Interestingly, as Daube’s remarks imply, Australia is doing very
well—latest figures show that smoking prevalence there has
dipped to 16.1% 20
Commercial exploitation of reduction
This more complex view alerts us to potential hazards that lurk
in the real world, beyond the consulting room and the
randomised controlled trial. In particular, two corporate players
come into focus: the pharmaceutical and tobacco industries.
The drug industry set the ball rolling with a desire to increase
the profitability of its nicotine replacement products. One way
to do this was to turn these cessation products, which require
only short term use, into maintenance products. If patches, like
cigarettes, were used for decades they would deliver the same
lucrative returns. Applications were therefore made to extend
product licences, first for use in cutting down smoking with a
view to quitting and then simply for cutting down. These
succeeded and culminated in NICE endorsing lifetime use of
nicotine replacement therapy.21 But then things started to
unravel.
Tobacco multinationals were watching carefully and saw
opportunities in the more nuanced stand on nicotine. They are,
as they long ago acknowledged, “in the business of selling
nicotine, an addictive drug,”22 and this practice was being subtly
but unmistakably legitimised. They also welcomed the move
from outright cessation to a more forgiving agenda of harm
reduction.23 As long ago as 2009, British American Tobacco
(BAT) was presenting to NICE on the commercial benefits this
offered: “We aspire to reduce the harm caused by smoking by
evolving our products to a portfolio of commercially successful
lower risk products, to meet consumer and societal
expectations.”24
This promised move to lower risk products has, with Orwellian
skill, now become a “risk spectrum” of products “based on their
toxicant levels. Conventional cigarettes carry the highest risk
while appropriately regulated nicotine products, which offer
nicotine without tobacco or smoke toxicants, are substantially
less risky.”25 It is this “pragmatic approach” that means that
BAT can continue selling cigarettes but devolve responsibility
for risk taking to its customers.
The e-cigarette has arrived noisily into this scene, with its
capacity to beat traditional NRT by replicating the nicotine spike
of tobacco cigarettes. The UK’s laissez-faire regime has enabled
an explosion of new products along with intense promotion in
every available channel. The tobacco multinationals have leapt
enthusiastically into this market; all now have major e-cigarette
interests.26 This is not a consumer movement but the full
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onslaught of corporate capital in hot pursuit of a profitable
opportunity.
In conclusion, any move away from tobacco by smokers is to
be welcomed, and cutting down is no exception. However,
smoking is about much more than nicotine addiction, and when
addiction becomes overly dominant in the policy debate, as it
now has in the UK, the principal beneficiaries are likely to be
the multinational tobacco companies.
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